DE2922488A1 - 2-Hydroxy-4-amino-6-methyl-isophthalic acid - and 2,6-di:acetyl-3-hydroxy-5-methylphenol derivs. with cardiovascular activity - Google Patents
2-Hydroxy-4-amino-6-methyl-isophthalic acid - and 2,6-di:acetyl-3-hydroxy-5-methylphenol derivs. with cardiovascular activityInfo
- Publication number
- DE2922488A1 DE2922488A1 DE19792922488 DE2922488A DE2922488A1 DE 2922488 A1 DE2922488 A1 DE 2922488A1 DE 19792922488 DE19792922488 DE 19792922488 DE 2922488 A DE2922488 A DE 2922488A DE 2922488 A1 DE2922488 A1 DE 2922488A1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- hydroxy
- general formula
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000005792 cardiovascular activity Effects 0.000 title abstract 3
- BFXMWMNSBSRZTI-UHFFFAOYSA-N 4-amino-2-hydroxy-6-methylbenzene-1,3-dicarboxylic acid Chemical compound OC1=C(C(=O)O)C(=CC(=C1C(=O)O)N)C BFXMWMNSBSRZTI-UHFFFAOYSA-N 0.000 title 1
- -1 pyrrolidino, piperidino Chemical group 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- GBIOAZWZICXODO-UHFFFAOYSA-N 1-methyl-1,4-diazepine Chemical compound CN1C=CC=NC=C1 GBIOAZWZICXODO-UHFFFAOYSA-N 0.000 claims 1
- DMCVVFIWYIKAEJ-UHFFFAOYSA-N 4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCNCC1 DMCVVFIWYIKAEJ-UHFFFAOYSA-N 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- XFJIXARLDYKCPG-UHFFFAOYSA-N 3,5-diacetyl-2,6-dimethylpyran-4-one Chemical compound CC(=O)C1=C(C)OC(C)=C(C(C)=O)C1=O XFJIXARLDYKCPG-UHFFFAOYSA-N 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- JISSLTOKQRHSMJ-UHFFFAOYSA-N diethyl 2,6-dimethyl-4-oxopyran-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)OC(C)=C(C(=O)OCC)C1=O JISSLTOKQRHSMJ-UHFFFAOYSA-N 0.000 description 2
- JLVWYWVLMFVCDI-UHFFFAOYSA-N diethyl benzene-1,3-dicarboxylate Chemical compound CCOC(=O)C1=CC=CC(C(=O)OCC)=C1 JLVWYWVLMFVCDI-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- TWWSMHPNERSWRN-UHFFFAOYSA-N acetaldehyde diisopropyl acetal Natural products CC(C)OC(C)OC(C)C TWWSMHPNERSWRN-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- ZKXWKVVCCTZOLD-UHFFFAOYSA-N copper;4-hydroxypent-3-en-2-one Chemical compound [Cu].CC(O)=CC(C)=O.CC(O)=CC(C)=O ZKXWKVVCCTZOLD-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
2-Hydroxy-4-methyl-benzolverbindungen, Verfahren zu2-Hydroxy-4-methyl-benzene compounds, method too
ihrer Herstellung und ihre Verwendung Die Erfindung betrifft neue 2-Hydroxy-4-methyl-benzolverbindungen, die als Arzneimittel geeignet sind.their manufacture and use The invention relates to new 2-hydroxy-4-methyl-benzene compounds that are suitable as pharmaceuticals are.
Die Erfindung ist in den Patentansprüchen definiert.The invention is defined in the claims.
Die Reste R2 und R3 können gleich oder verschieden sein.The radicals R2 and R3 can be identical or different.
R2, R3 und R5 können Methyl, Athyl, n-Propyl, i-Propyl, n-Butyl, i-Butyl oder t-Butyl bedeuten und sind vorzugsweise Methyl oder Methyl.R2, R3 and R5 can be methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl and are preferably methyl or methyl.
Wenn R2 + R3 + N C1- - bis C4-Dialkyl-morpholino bedeuten, so ist Dimethylmorpholino, insbesondere 2,6-Dimethylmorpholino, bevorzugt.If R2 + R3 + N are C1- to C4-dialkylmorpholino, then is Dimethylmorpholino, in particular 2,6-dimethylmorpholino, is preferred.
Wenn R6 einen substituierten Phenylrest bedeutet, so steht der Substituent vorzugsweise in m-Stellung zur Verknüpfungsstelle. Bedeutet R6 einen C1- bis C4-Alkylrest oder enthält R einen solchen Rest, so sind Methyl und Äthyl bevorzugt.If R6 is a substituted phenyl radical, then the substituent is preferably in the m-position to the connection point. If R6 is a C1 to C4 alkyl radical or if R contains such a radical, methyl and ethyl are preferred.
Bevorzugte Salze sind die Hydrohalogenide, Hydrogenmaleinate und Hydrogenfumarate.Preferred salts are the hydrohalides, hydrogen maleate and hydrogen fumarates.
Erfindungsgemässe Verbindungen sind beispielsweise 2,6-Diacetyl-5-methyl-3-(4-cyano-4-phenyl-piperidino)-phenol vom F. 160 - 162 0C; 2-Hydroxy-6-methyl-4-(2,6-dimethyl-N-morpholino)-isophthalsäurediäthylester vom F. 63 - 65 OC; 2-Hydroxy-6-methyl-4-(N-1,2,3,4-tetrahydroisochinolino)-isophthalsäurediäthylester vom F. 121 - 123 OC; 2,6-Diacetyl-5-methyl-3-(4-benzyl-N-piperazino)-phenol vom F. 88 - 90 OC und 2-Hydroxy-6-methyl-4-~T-(3-trifluormethylphenyl)-N-piperazino/-isophthalsäurediäthylester vom F. 109 - 111 °C Das als Ausgangsprodukt des erfindungsgemässen Verfahrens dienende 3,5-Diacetyl-2,6-dimethyl-4H-pyran-4-on (Verbindung der allgemeinen Formel II mit R1 = Methyl) kann man nach der Verfahrensweise von Thomas und Lefevre (Bull. Soz. Chim. Fr., Bd. 50 (2), Seite 193 (1888)) aus Kupferacetylacetonat und Phosgen synthetisieren. Zur Herstellung der Ausgangsverbindungen der allgemeinen Formel II, in denen der Rest R1 = oR5 ist, kann man das Kupfersalz des entsprechenden Acetessigsäureesters mit Phosgen nach der Methode von Conrad und Guthzeit (Ber. Dtsch. Chem. Ges., Bd. 19, Seite 22 (1886); Bd. 20, Seite 152 (1887)) herstellen. Der nach dieser Verfahrensweise hergestellte 2,6-Dimethyl-4H-pyran-4-on-3,5-dicarbonsäurediäthylester hat einen F. 81 OC (Äthanol).Compounds according to the invention are, for example, 2,6-diacetyl-5-methyl-3- (4-cyano-4-phenyl-piperidino) -phenol mp 160-162 ° C; 2-Hydroxy-6-methyl-4- (2,6-dimethyl-N-morpholino) -isophthalic acid diethyl ester from m.p. 63-65 ° C; 2-Hydroxy-6-methyl-4- (N-1,2,3,4-tetrahydroisoquinolino) isophthalic acid diethyl ester from mp 121-123 OC; 2,6-Diacetyl-5-methyl-3- (4-benzyl-N-piperazino) -phenol vom F. 88-90 ° C. and 2-hydroxy-6-methyl-4- ~ T- (3-trifluoromethylphenyl) -N-piperazino / isophthalic acid diethyl ester with a temperature of 109 - 111 ° C As the starting product of the invention Process serving 3,5-diacetyl-2,6-dimethyl-4H-pyran-4-one (compound of the general Formula II with R1 = methyl) can be prepared using the procedure of Thomas and Lefevre (Bull. Soz. Chim. Fr., Vol. 50 (2), page 193 (1888)) from copper acetylacetonate and Synthesize phosgene. For the preparation of the starting compounds of the general Formula II, in which the radical R1 = OR5, you can use the copper salt of the corresponding Acetoacetic acid ester with phosgene according to the method of Conrad and Guthzeit (Ber. German Chem. Ges., Vol. 19, p. 22 (1886); Vol. 20, page 152 (1887)). The 2,6-dimethyl-4H-pyran-4-one-3,5-dicarboxylic acid diethyl ester prepared by this procedure has an F. 81 OC (ethanol).
Geht man zur Durchführung des erfindungsgemässen Verfahrens von 3,5-Diacetyl-2,6-dimethyl-4H-pyran-4-on aus, so beträgt die Reaktionszeit im allgemeinen 0,5 bis 2 Stunden bei einer Temperatur von 50 bis 150 OC, insbesondere etwa 100 °C. Ein Lösungsmittel ist im allgemeinen nicht notwendig.If the process according to the invention is carried out from 3,5-diacetyl-2,6-dimethyl-4H-pyran-4-one off, the reaction time is generally 0.5 to 2 hours at one temperature from 50 to 150.degree. C., in particular about 100.degree. A solvent is generally unnecessary.
Geht man von Ausgangsverbindungen der allgemeinen Formel II aus, in denen R1 = OR5 ist, so arbeitet man vorzugsweise in Gegenwart eines Lösungsmittels, wie äthanol, und erhitzt unter Rückfluss ca. 1 bis 50 Stunden. In manchen Fällen, z.B.If one proceeds from starting compounds of the general formula II, in where R1 = OR5, it is preferably carried out in the presence of a solvent, like ethanol, and heated under reflux for about 1 to 50 hours. In some cases, e.g.
bei Verwendung von 1,2,3,4-Tetrahydroisochinolin oder Dialkylmorpholinen, kann die Umsetzung auch ohne Lösungsmittel in der Schmelze erfolgen, wobei die Umsetzungszeit dann 1 bis 3 Stunden beträgt.when using 1,2,3,4-tetrahydroisoquinoline or dialkylmorpholines, the reaction can also be carried out in the melt without a solvent, the reaction time being then 1 to 3 hours.
Die Säureadditionssalze erhält man durch Umsetzung mit einer Säure in bekannter Weise.The acid addition salts are obtained by reaction with an acid in a known way.
Man erhält durch die erfindungsgemässe Umsetzung von Verbindungen der allgemeinen Formel II, worin R1 Methyl bedeutet mit einem sekundären Amin erfindungsgencsse Verbindungen der allgemeinen Formel Diese kann man nach der Verfahrensweise von Föhlisch (Ber.The inventive reaction of compounds of the general formula II in which R1 denotes methyl with a secondary amine gives compounds of the general formula according to the invention This can be done according to the method of Föhlisch (Ber.
Dtsch. Chem. Ges., Bd. 104, Seite 348 (1971) ) mit einem Dimethylformamiddiacetaly beispielsweise dem Dimethylacetal oder Diisopropylacetal, zu Verbindungen der allgemeinen Formel umsetzen. So erhält man beispielsweise die Verbindung l-Acetyl-3-(3-dimethylamino-acryloyl)-2-hydroxy-6-methyl-4-(piperidin-1-yl)-benzol vom F. 138 OC, Setzt man dieses Enaminoketon (Verbindung der allgemeinen Formel IV) mit Säure,z.B. mit verdünnter Schwefelsäure, vorzugsweise in der Wärme, um, so erhält man Chromonverbindungen der allgemeinen Formel Die Cyclisierung erfolgt nach der Vorschrift von Föhlisch (Ber. Dtsch. Chem. Ges., Bd. 104, Seite 348 (1971) ). Eine so hergestellte Verbindung ist beispielsweise 8-Acetyl-7-methyl-5-(piperidin-1-yl) -4H-benzo/b~7pyran-4-on vom F. 141 bis 142 °C.German Chem. Ges., Vol. 104, page 348 (1971)) with a dimethylformamide diacetaly, for example dimethyl acetal or diisopropyl acetal, to give compounds of the general formula realize. For example, the compound l-acetyl-3- (3-dimethylamino-acryloyl) -2-hydroxy-6-methyl-4- (piperidin-1-yl) benzene with a melting point of 138 OC is obtained. Compound of the general formula IV) with acid, for example with dilute sulfuric acid, preferably in the heat, to obtain chromone compounds of the general formula The cyclization is carried out according to the instructions of Föhlisch (Ber. Dtsch. Chem. Ges., Vol. 104, page 348 (1971)). A compound prepared in this way is, for example, 8-acetyl-7-methyl-5- (piperidin-1-yl) -4H-benzo / b ~ 7pyran-4-one with a melting point of 141 to 142 ° C.
Die Chromonverbindungen (V) lassen sich mit einem Hydrazin der allgemeinen Formel 8 H2N-NHR8 , VI worin R8 Wasserstoff, Methyl, Athyl oder Phenyl bedeutet, zu Benzolverbindungen der allgemeinen Formel umsetzen. Die Umsetzung erfolgt vorzugsweise unter Rückfluss in einem Lösungsmittel, insbesondere Äthanol. Die Verfahrensdauer beträgt mehrere Stunden. Man kann so z.B.The chromone compounds (V) can be converted to benzene compounds of the general formula with a hydrazine of the general formula 8H2N-NHR8, VI in which R8 is hydrogen, methyl, ethyl or phenyl realize. The reaction is preferably carried out under reflux in a solvent, in particular ethanol. The procedure takes several hours. You can for example
l-Acetyl-2-hydroxy-6-methyl-3-(1-phenyl-pyrazol-5-yl)-4-(piperidin-1-yl)-benzol vom F. 142 OC, l-Acetyl-2-hydroxy-6-methyl-3-(1-methyl-pyrazol-5-yl)-4-(piperidin-1-yl)-benzol vom F. 162 CC oder l-Acetyl-2-hydroxy-6-methyl-3-(pyrazol-5-yl)-4-(piperidin-1-yl)-benzol vom F. 195 OC synthetisieren.1-Acetyl-2-hydroxy-6-methyl-3- (1-phenyl-pyrazol-5-yl) -4- (piperidin-1-yl) -benzene vom F. 142 OC, 1-acetyl-2-hydroxy-6-methyl-3- (1-methyl-pyrazol-5-yl) -4- (piperidin-1-yl) -benzene vom F. 162 CC or 1-acetyl-2-hydroxy-6-methyl-3- (pyrazol-5-yl) -4- (piperidin-1-yl) -benzene synthesize from F. 195 OC.
Die Benzolverbindungen (VII) kann man aber auch herstellen, indem man eine Enaminoketonverbindung (IV) unmittelbar mit einer Hydrazinverbindung (VI) in einem Lösungsmittel, vorzugsweise Äthanol, in Gegenwart einer Säure, z.B. Eisessig, umsetzt. Die Umsetzung erfolgt insbesondere in der Wärme, z.B. unter Rückfluss.The benzene compounds (VII) can also be prepared by one enaminoketone compound (IV) directly with a hydrazine compound (VI) in a solvent, preferably ethanol, in the presence of an acid, e.g. glacial acetic acid, implements. The conversion takes place in particular in the heat, e.g. under reflux.
Die erfindungsgemässen Verbindungen der Formel I haben vor allem Wirkungen auf Herz und Kreislauf. Auch die Verbindungen der allgemeinen Formel VII haben arzneiliche, vor allem Herz- und Kreislaufwirkungen.The compounds of the formula I according to the invention have above all effects on the heart and circulation. The compounds of the general formula VII also have medicinal, especially cardiovascular effects.
Die erfindungsgemässen Verbindungen können zu üblichen flüssigen oder festen Arzneimittelzubereitungen verarbeitet werden, beispielsweise zu Dragees, Tabletten, Suppositorien und Lösungen, auch für die Injektion. Hierzu werden übliche Träger- und Verdünnungsmittel und übliche Verfahrensweisen verwendet.The compounds according to the invention can be added to conventional liquid or solid pharmaceutical preparations are processed, for example into coated tablets, Tablets, suppositories and solutions, also for injection. For this purpose, the usual Carriers and diluents and conventional procedures used.
Die orale Einzeldosis beträgt 1 bis 10 mg/kg, die orale Tagesdosis beträgt 3 bis 30 mg/kg. Die parenterale Einzeldosis beträgt 0,1 bis 2 mg/kg, die parenterale Tagesdosis beträgt ,3 bis 6 mg/kg.The oral single dose is 1 to 10 mg / kg, the oral daily dose is 3 to 30 mg / kg. The single parenteral dose is 0.1 to 2 mg / kg, the parenteral daily dose is 3 to 6 mg / kg.
Beispiel 1 1 ,3-Diacetyl-2-hydroxy-4-methyl-6-(piperidin-1-yl)-benzol 2 g (0,01 Mol) 355-Diacetyl-2,6-dimethyl-4H-pyran-4-on werden ohne Lösungsmittel mit 950 mg (0,011 Mol) Piperidin 1 1/2 Stunden bei 100 OC gehalten. Nach Zugabe von wenig Äthanol kristallisiert die gesuchte Verbindung in gelblichen Kristallen; F. 95-96 OC; Ausb. 2,2 g (84 % d. Th.).Example 1 1,3-Diacetyl-2-hydroxy-4-methyl-6- (piperidin-1-yl) -benzene 2 g (0.01 mol) of 355-diacetyl-2,6-dimethyl-4H-pyran-4-one become without a solvent with 950 mg (0.011 mol) of piperidine held at 100 ° C. for 1 1/2 hours. After adding from a little ethanol the sought compound crystallizes in yellowish crystals; F. 95-96 OC; Yield 2.2 g (84% of theory).
Beispiel 2 1,3-Diacetyl-2-hydroxy-4-methyl-6-(pyrrolidin-1-yl)-benzol 2 g (0,01 Mol) 3,5-Diacetyl-2,6-dimethyl-4H-pyran-4-on werden mit 690 mg (0,011 Mol) Pyrrolidin nach der Verfahrensweise des Beispiels 1 behandelt.Example 2 1,3-Diacetyl-2-hydroxy-4-methyl-6- (pyrrolidin-1-yl) -benzene 2 g (0.01 mol) of 3,5-diacetyl-2,6-dimethyl-4H-pyran-4-one are mixed with 690 mg (0.011 Mol) pyrrolidine treated according to the procedure of Example 1.
Gelbliche Kristalle aus Äthanol, F. 129 OC; Ausb. 1,8 g (71 % d. Th.).Yellowish crystals from ethanol, m.p. 129 OC; Yield 1.8 g (71% of theory).
Beispiel 3 1 2-hydroxy-4-methyl-6-(morpholin-4-y)-be 2 g (0,01 Mol) 3,5-Diacetyl-2,6-dimethyl-4H'-pyran-4-on werden mit 900 mg Morpholin nach der Verfahrensweise des Beispiels 1 behandelt.Example 3 1 2-hydroxy-4-methyl-6- (morpholin-4-y) -be 2 g (0.01 mol) 3,5-Diacetyl-2,6-dimethyl-4H'-pyran-4-one are mixed with 900 mg of morpholine according to the procedure of Example 1 treated.
Gelbliche Kristalle aus Athanol; F. 78 OC; Aush. 1,8 g (69 % d. Th.).Yellowish crystals of ethanol; M.p. 78 OC; Excluding 1.8 g (69% of theory).
Beispiel 4 1,5-Diacetyl-2-methyloxy-4-methyl-6-tpiperidin-1-yl)-benzol 0,5 g (0,002 Mol) 1,3-Diacetyl-2-hydroxy-4-methyl-6-(piperidinl-yl)-benzol werden nach der Vorschrift von Kostanecki (Ber. Dtsch. Chem. Ges., Bd. 35, Seite 1669 (1902)) mit Dimethylsulfat und KOH methyliert.Example 4 1,5-Diacetyl-2-methyloxy-4-methyl-6-tpiperidin-1-yl) -benzene 0.5 g (0.002 mol) of 1,3-diacetyl-2-hydroxy-4-methyl-6- (piperidinl-yl) -benzene according to the instructions of Kostanecki (Ber. Dtsch. Chem. Ges., Vol. 35, page 1669 (1902)) methylated with dimethyl sulfate and KOH.
Farblose Kristalle aus Äthanol; F. 75 OC; Ausb. 480 mg (93 % d. Th.).Colorless crystals of ethanol; M.p. 75 OC; Yield 480 mg (93% of theory).
Beispiel 5 2-Hydroxy-4-methyl-6-(piperidin-1-yl)-benzol-1,3-dicarbonsäure-diäthylester 2 g (0,0074 Mol) 2,6-Dimethyl-4H-pyran-4-on-3,5-dicarbonsäurediäthylester werden mit 1,9 g t0,0223 Mol) Piperidin in 5 ml Äthanol 1 Stunde rückfliessend erhitzt. Nach dem Abkühlen farblose Kristalle aus Athanol; F. 56 OC; Ausb. 1>4 g (58 % d. Th.).Example 5 2-Hydroxy-4-methyl-6- (piperidin-1-yl) -benzene-1,3-dicarboxylic acid diethyl ester 2 g (0.0074 mol) of 2,6-dimethyl-4H-pyran-4-one-3,5-dicarboxylic acid diethyl ester refluxed with 1.9 g t0.0223 mol) of piperidine in 5 ml of ethanol for 1 hour. After cooling, colorless crystals of ethanol; F. 56 OC; Yield 1> 4 g (58% d. Th.).
Ende der BeschreibungEnd of description
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792922488 DE2922488A1 (en) | 1979-06-01 | 1979-06-01 | 2-Hydroxy-4-amino-6-methyl-isophthalic acid - and 2,6-di:acetyl-3-hydroxy-5-methylphenol derivs. with cardiovascular activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792922488 DE2922488A1 (en) | 1979-06-01 | 1979-06-01 | 2-Hydroxy-4-amino-6-methyl-isophthalic acid - and 2,6-di:acetyl-3-hydroxy-5-methylphenol derivs. with cardiovascular activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2922488A1 true DE2922488A1 (en) | 1980-12-11 |
Family
ID=6072343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792922488 Withdrawn DE2922488A1 (en) | 1979-06-01 | 1979-06-01 | 2-Hydroxy-4-amino-6-methyl-isophthalic acid - and 2,6-di:acetyl-3-hydroxy-5-methylphenol derivs. with cardiovascular activity |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2922488A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020500A3 (en) * | 2000-09-01 | 2003-07-31 | Icos Corp | Materials and methods to potentiate cancer treatment |
| US8404681B2 (en) | 2003-03-24 | 2013-03-26 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
-
1979
- 1979-06-01 DE DE19792922488 patent/DE2922488A1/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020500A3 (en) * | 2000-09-01 | 2003-07-31 | Icos Corp | Materials and methods to potentiate cancer treatment |
| US7179912B2 (en) | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| US8242115B2 (en) | 2000-09-01 | 2012-08-14 | Luitpold Pharmaceuticals, Inc. | Materials and methods to potentiate cancer treatment |
| US8404681B2 (en) | 2003-03-24 | 2013-03-26 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69716062T2 (en) | BENZOFURANE DERIVATIVES AND THEIR USE | |
| CH616673A5 (en) | ||
| CH624395A5 (en) | ||
| DE3309596A1 (en) | 2-SUBSTITUTED 1- (3'-AMINOALKYL) -1,2,3,4-TETRAHYDRO-SS-CARBOLINE, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCT | |
| DD215542A5 (en) | PROCESS FOR THE PREPARATION OF 4-CYANO-PYRIDAZINES | |
| DE3326148C2 (en) | ||
| EP0380712B1 (en) | Process for the preparation of 2,6-dichlorodiphenylaminoacetic-acid derivatives | |
| DE2824554A1 (en) | 1-PHENYL-3,3-DICHLORO-2-AZETIDINONE | |
| DE1925956A1 (en) | Chemical processes and products | |
| DE2922488A1 (en) | 2-Hydroxy-4-amino-6-methyl-isophthalic acid - and 2,6-di:acetyl-3-hydroxy-5-methylphenol derivs. with cardiovascular activity | |
| DE2707270A1 (en) | Pyrazolo-benzodiazepine derivs. - used esp. for lowering uric acid levels | |
| DE2819372C2 (en) | ||
| DE3423429A1 (en) | SUBSTITUTED PHENOXYALKYLAMINOPROPANOLE, METHOD FOR THE PRODUCTION AND USE THEREOF, AND PREPARATIONS CONTAINING THESE COMPOUNDS | |
| CH493538A (en) | 11-aminodibenz b f 1 4-oxa-thia-or dia-zepines | |
| DE1076691B (en) | Process for the preparation of phenthiazine derivatives | |
| DE2943326C2 (en) | ||
| DE2345422A1 (en) | N-Substd.-4,4-dimethyl-isoquinolin-1,3-diones - as hypotensive agents also showing bradycardisant, antiarythmic and sedative effects | |
| DE2912445A1 (en) | 2-Methylene-2,3-di:hydro-3-oxo-4H-1,4-benzothiazine-1,1-di:oxide(- s) - prepd. by reacting 2-bis-alkylthio-methylene cpds. with amine cpds. | |
| EP0303179A1 (en) | 1,2-Diamino compounds, processes for their preparation and medicines containing these compounds | |
| AT359073B (en) | METHOD FOR PRODUCING NEW PIPERAZINE OR PIPERIDINE DERIVATIVES AND THEIR SALTS | |
| AT258927B (en) | Process for the preparation of new 4,5-dihalo-1,2-dihydro-3,6-pyridazinedione compounds | |
| EP0199323A2 (en) | 4-Substituted aminoalkylidene-3-aryl-5(4H) isoxazolines, process for their preparation, medicaments containing them and their use | |
| AT370406B (en) | METHOD FOR PRODUCING NEW ALLYLAMINE DERIVATIVES AND THEIR ACID ADDITION SALTS | |
| EP0000750A1 (en) | 1,2-Benzisothiazoles and process for their preparation | |
| DE3850304T2 (en) | 3-arylcarbamoyl-5-aminomethyl-oxazolidines and their salt with pharmacologically acceptable acids. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |